Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivacaftor in CF Children Aged 3-5 Years with Gating Mutations
NCT02742519Phase 3Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of ivacaftor in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Lung Clearance Index 2.5 at 8 weeks. Started May 2016; status: terminated.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02742519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02742519.